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Background: Because access to care is limited in settings with high mortal-
ity, exclusive reliance on the current recommendation of 7–10 days of par-
enteral antibiotic treatment is a barrier to provision of adequate treatment 
of newborn infections.
Methods: We are conducting a trial to determine if simplified antibiotic 
regimens with fewer injections are as efficacious as the standard course of 
parenteral antibiotics for empiric treatment of young infants with clinical 
signs suggestive of severe infection in 4 urban hospitals and in a rural sur-
veillance site in Bangladesh. the reference regimen of intramuscular pro-
caine-benzyl penicillin and gentamicin given once daily for 7 days is being 
compared with (1) intramuscular gentamicin once daily and oral amoxicil-
lin twice daily for 7 days and (2) intramuscular penicillin and gentamicin 
once daily for 2 days followed by oral amoxicillin twice daily for additional 
5 days. All regimens are provided in the infant’s home. the primary out-
come is treatment failure (death or lack of clinical improvement) within 
7 days of enrolment. the sample size is 750 evaluable infants enrolled per 
treatment group, and results will be reported at the end of 2013.
Discussion: the trial builds upon previous studies of community case 
management of clinical severe infections in young infants conducted by 
our research team in Bangladesh. the approach although effective was not 
widely accepted in part because of feasibility concerns about the large num-
ber of injections. the proposed research that includes fewer doses of paren-
teral antibiotics if shown efficacious will address this concern.
Key Words: safety, efficacy, simplified antibiotic regimens, young infants, 
clinical severe infection
(Pediatr Infect Dis J 2013;32:S12–S18)
An estimated 3.0 million annual neonatal deaths occur glob-ally; 99% of these deaths occur in developing countries.1–4 
In many settings, neonatal and infant mortality now make up the 
vast majority of under-5 child deaths. For example, in Bangladesh, 
57% of under-5 deaths occur within the first 28 days after birth and 
another 23% take place in the postneonatal period.5 Approximately 
10–20% of newborns develop life-threatening infections6 and one-
third to one-half of all neonatal deaths are due to infection,1,7–9 
including sepsis, pneumonia, tetanus, meningitis and diarrhea. 
timely and appropriate treatment can avert most of these deaths.6,10
the World Health Organization (WHO) recommends that 
all cases of clinical severe infection in neonates and young infants 
(0–59 days old) be treated in hospitals with a 7- to 10-day course 
of injectable antibiotics—penicillin or ampicillin and gentamicin. 
In low-resource settings, however, reliance on a strategy of hos-
pitalization of young infants with clinical severe infections has a 
number of inherent disadvantages. parents/caregivers often con-
sider care-seeking outside the home to be unacceptable in the early 
postpartum period, or they may not be able to travel to a health 
facility; upon reaching the facility, infants may receive inadequate 
treatment because of barriers due to cost, under-staffing or lack of 
available beds and supplies.11–15 Hospitalization increases the risk 
of exposure to multidrug-resistant nosocomial pathogens that are 
increasingly difficult to treat16,17 and raises the cost of health care.18
Strategies for community-based management of severe 
infections in young infants have been developed and evaluated 
in several research settings.8,19,20 A cluster-randomized controlled 
trial of a package of maternal and neonatal interventions, which 
included assessment and management of newborns by village-
based community health workers, was conducted by our group in 
Sylhet district, Bangladesh. neonates with signs of severe infec-
tion were referred to a qualified provider or treated in the home 
with intramuscular procaine penicillin and gentamicin (treatment 
regimen included a total of 10 days of gentamicin and procaine 
penicillin. Dosage of gentamicin was adjusted based on neonate’s 
weight as follows: 10 mg every other day if <2.0 kg, 10 mg/day if 
2.0–2.5 kg and 13.5 mg/day if >2.5 kg. Dosage for penicillin was 
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80,000 units if <2.0 kg and 160,000 units if ≥2.0 kg.) if the care-
taker declined referral but consented to home treatment. the rate 
of referral compliance was 34% among those diagnosed as being 
in the severe disease category, and another 43% accepted home 
treatment; the case fatality rate for neonates treated by community 
health workers was statistically not different from that of neonates 
treated by doctors and other medically qualified providers and was 
78% lower than for those who received no treatment or were treated 
by untrained providers (adjusted hazard ratio 0.22, 95% confidence 
interval [CI]: 0.07–0.71).21 In a trial providing home-based treat-
ment with a regimen of oral co-trimoxazole and intramuscular gen-
tamicin, Bang et al22 reported a 60% reduction in neonatal infection 
case fatality. One barrier to scaling up findings from these trials 
is that major challenges are associated with providing parenteral 
antibiotic therapy in the community. It is resource intensive to 
train community-based health workers to provide injections and to 
ensure supply of antibiotics and safe administration of parenteral 
antibiotics daily for 7 to 10 days.
evidence suggests that oral antibiotic therapy also reduces 
mortality in neonates and young infants with suspected infections.10 
A meta-analysis of trials of community-based case management of 
pneumonia found a 27% reduction in neonatal mortality and a 20% 
reduction in infant mortality.23 Five of the 7 studies included in the 
meta-analysis used oral antibiotic regimens. In an open-label trial 
in pakistan, 3- to 59-month-old children (n = 2037) with severe 
pneumonia were randomly allocated to either (1) hospitalization 
and parenteral ampicillin (100 mg/kg per day in 4 doses) for 48 
hours, followed by 3 days of oral amoxicillin (80–90 mg/kg per day 
in 2 doses), or (2) home-based treatment for 5 days with oral amox-
icillin (80–90 mg/kg per day in 2 doses).24 At 7 days after the start 
of treatment, no difference in treatment failure rates was observed 
between the hospitalized group (8.6%) and the ambulatory group 
(7.5%; risk difference 1.1%; 95% CI: –1.3 to 3.5). High failure 
rates, however, were associated with age 3–5 months, very fast 
breathing (>70 breaths per minute for children <12 months old) and 
low weight for age, suggesting that providing oral antibiotics alone 
may be inadequate for young infants with clinical severe infection. 
Alternatives for these infants include restricting the number of 
injectable antibiotics either by combining a initial short course of 
parenteral antibiotics with a switch to oral antibiotics or a combina-
tion of injectable and oral antibiotics.10
In 2007, a global consultation convened by the Saving 
newborn lives Initiative of Save the Children, the united States 
Agency for International Development and the WHO concluded 
that there was insufficient evidence on infection management in 
young infants in community-based settings to make policy recom-
mendations for global programs. the consultation highlighted the 
need for research to test combinations of low cost existing oral and 
intramuscular antibiotic regimens that might feasibly be imple-
mented in first-level facilities and the community, and that would 
be acceptable in settings characterized by weak health systems.
METHODS
Study Design
We are conducting a trial in Bangladesh to determine if 2 
home-based antibiotic regimens are as efficacious as the stand-
ard regimen of intramuscular procaine-benzyl penicillin and gen-
tamicin given once daily each for 7 days for the empiric treatment 
of young infants (age 0–59 days) with clinical signs suggestive of 
severe infection (clinical severe infection). the 2 alternative regi-
mens are (1) intramuscular gentamicin once daily and oral amoxi-
cillin twice daily for 7 days and (2) intramuscular penicillin and 
gentamicin once daily for 2 days followed by oral amoxicillin twice 
daily for 5 days. the primary hypothesis is that the proportion of 
infants who fail treatment will be 10% in the reference group and 
each of the alternative treatment groups. the null hypothesis is 
that any one of the alternative therapies is inferior and will yield a 
treatment failure proportion that is at least 5% points higher than 
that of the standard therapy group. the null hypothesis will be 
rejected if the upper bound of a 95% CI around the absolute dif-
ference (alternative minus standard) is less than 5.0%. the trial’s 
secondary objectives are (1) to identify baseline clinical predictors 
of treatment failure in severe infections in young infants and (2) to 
determine the proportion of infants with relapse, defined as young 
infants who were considered cured by day 7 but developed any of 
the signs of clinical severe infection by day 14.
Setting, Enrollment and Randomization
the study recruits young infants from the outpatient 
departments of Dhaka Shishu (children) Hospital, Shishu Sasthya 
Hospital in Dhaka, Institute of Child and mother Health Hospital 
in Dhaka, Chittagong ma O Shishu Hospital in Chittagong and a 
rural surveillance sites in Sylhet, Bangladesh. All 4 hospitals are 
in the urban areas of 2 major cities of Bangladesh, receive young 
infants with very similar complaints and use similar approaches 
to clinical management of severe infections in young infants. In 
the rural site, all pregnant women in the study area are identi-
fied by female community health workers (CHW) through estab-
lished pregnancy surveillance and are offered a standard package 
of antenatal counseling. Families and birth attendants notify the 
CHW as promptly as possible after a birth has occurred. After 
birth, CHWs aim to visit all newborns in the home within 6 hours 
of birth and not later than 24 hours. this early postnatal visit is 
important to capture early-onset infections. the general health 
status of the infant is assessed by the CHW using criteria from 
the WHO Young Infant Study Group.25 the CHW returns on days 
2, 6, 13, 20, 27, 34, 41, 48 and 59 after birth to inquire about any 
illness of the infant in the intervening period and to reassess the 
status of the infant. CHWs refer infants meeting the criteria for 
clinical severe infection to 1 of 2 designated hospitals for further 
evaluation and care.
Recruitment and participation procedures are summarized in 
Figure 1. Research assistants who work for the study screen young 
infants presenting to the outpatient departments of the participating 
hospitals to determine if age and place of residence meet initial 
eligibility criteria. potentially eligible infants are then screened by 
the study physician for signs of clinical severe infection accord-
ing to the inclusion and exclusion criteria described below. Infants 
with ≥1 inclusion criteria and no exclusion criteria are considered 
clinically eligible; however, study physicians first recommend hos-
pitalization before enrolment in the trial. If no hospital bed is avail-
able, the infant is referred to another hospital. If the infant’s family 
refuses hospitalization or referral, the study physician presents the 
option for home treatment through study participation.
to be eligible for inclusion, infants must be 0–59 days of age, 
residents of a predefined geographical area based on accessibility for 
follow-up visits, have at least 1 sign in the 5-sign algorithm for severe 
infection and none of the 12 signs of critically severe infection or dis-
ease and caregivers must refuse hospitalization or referral to another 
hospital as well as indicate that they plan to remain in the study area 
for at least 2 weeks. the study aims to exclude infants with signs of 
either very mild or very severe infections. thus, clinical inclusion 
criteria are based on a 5-sign algorithm that is a modified version 
of the WHO Young Infant Clinical Signs Study Group’s algorithm25; 
a comparison of the 2 algorithms is presented in table 1. Signs in 
this study’s algorithm include: (1) severe lower chest wall indrawing, 
(2) axillary temperature ≥100.4°F (≥38.0°C) confirmed by second 
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Infant registered at Hospital
Study physician 
assessment: Infant
clinically eligible?*
Infant receives 
routine clinical 
care
no
Family refuses
hospitalization?
Infant receives 
standard in-
hospital care
Options for other care presented: 
referral to another hospital.
Randomized to one of three 
treatment groups; blood and 
urine sample taken; treatment 
provided
Discharged home;
daily treatment and follow-up for 
days 2 - 8, day 11 and day 15
Infant cured?
Standard care at 
home or hospital, 
as per the opinion 
of senior 
pediatricians
Trial participation 
complete
yes
Triage by Research 
Assistant:
Eligible by age & place of 
residence?
yes
Hospital bed available?
no
yes
yes
no
no
yes
no
Counselor 
confirms that 
caregivers 
understand the 
physician’s 
recommendation 
regarding 
hospitalization 
* Infant meets at least one inclusion criteria and no exclusion criteria?
Study description provided and 
informed consent administered by 
study physician
Referral rejected or 
deemed not feasible
FIGURE 1. Trial profile.
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reading, (3) axillary temperature ≤95.9°F (≤35.5°C) confirmed by 
second reading, (4) lethargy (defined operationally as movement 
only upon stimulation by the examining physician) and (5) history of 
feeding problems, confirmed by poor suck on examination. the cri-
terion of respiratory rate ≥60 breaths per minute is excluded because 
data from previous studies in Bangladesh suggests that this sign alone 
is not predictive of severe illness.21 Infants with signs of very severe 
infection or disease are excluded because home-based treatment is 
felt to be potentially unsafe for this group. Very severe infection or 
disease is defined as the presence of any of the following signs: (1) 
unconsciousness, (2) history of or presence of convulsions present 
at assessment, (3) inability to feed, (4) apnea, (5) inability to cry, (6) 
cyanosis, (7) bulging fontanel, (8) major congenital malformations, 
(9) major bleeding, (10) surgical conditions needing hospital referral, 
(11) persistent vomiting after 3 attempts to feed the baby within half 
an hour or (12) physician’s suspicion of meningitis. Infants are also 
excluded from the study if they weigh <1500 g, have been hospital-
ized for illness in the last 2 weeks or were previously included in 
the study. legal guardians of infants meeting the study’s eligibility 
requirements are offered participation in the study through a written 
informed consent process. there are quality assurance teams in all 
study sites to monitor activities monthly with respect to quality and 
consistency of study procedures.
Infants are randomized to 1 of the 3 home treatment regi-
mens using site- and age-specific (<7 days or 7–59 days) computer-
generated randomization sequences with varying random block 
sizes of 3, 6 and 12. the allocation sequence for each site and age 
groups is placed in serially numbered, sealed and opaque envelopes 
and delivered to each site. After consent and enrollment, the study 
physician selects the next envelope, and the treatment correspond-
ing to the allocation code printed within the envelope is assigned 
to the infant.
Drug Dosages and Treatment Provision
Dosages (presented in table 2) were selected to optimize 
efficacy, safety and feasibility. extended-interval (24-hourly) gen-
tamicin regimens using doses of 4–5 mg/kg/day have been shown 
to be effective26,27 and remain within the range commonly used in 
the united States.28 For procaine penicillin, daily intramuscular 
doses of 25–50 mg/kg are recommended for neonatal infections,28 
and we have set a target range of 40–50 mg/kg per 24-hour dose. 
Amoxicillin is structurally almost identical to ampicillin, an antibi-
otic commonly used intravenously to treat invasive neonatal infec-
tions; however, amoxicillin is more commonly used in the oral form 
because of its high oral bioavailability. Although typically used at 
doses of 40–90 mg/kg/day (divided into 2 doses per day in the new-
born period), oral amoxicillin doses of 200–300 mg/kg/day have 
been shown to be safe in newborns treated for group B streptococ-
cal sepsis.29 For this study, a target dose ranging from 90 to 115 mg/
kg/day divided into 2 doses per day was chosen as this is similar 
to the dose of intravenous ampicillin recommended for the treat-
ment of neonatal infections that ranges from 75–200 mg/kg/day,28 
yet cautiously remains close to a standard “high-dose” amoxicillin 
regimen (90 mg/kg/day).
All enrolled infants are given the first doses of the assigned 
antibiotics and discharged home after counseling about home 
management. Study physicians provide intramuscular injections 
at home and assess infants daily for the next 7 days to assess for 
treatment failure; clinical assessments are conducted on day 11 
and day 15 to determine if a relapse has occurred. Caregivers are 
taught to give the oral antibiotics. If an infant vomits within 20 
minutes of oral dosing, the caregiver is instructed to readminister 
a complete dose; this is a safe approach, even if both of the doses 
were to be fully absorbed, because the total maximum daily dose of 
amoxicillin would be <200 mg/kg/day. If the infant vomits within 
TABLE 1. Comparison of WHO Young Infant Study Algorithm and the Trial Algorithm Used to Identify Infants With 
Clinical Severe Infection
WHO Young Infant Study-II Algorithm Algorithm in Use in This Trial
History of convulsion —
Respiratory rate ≥60/min —
Severe chest indrawing present Severe chest indrawing present
Fever: axillary temperature >99.5°F (>37.5°C) Fever: axillary temperature ≥100.4°F (≥38.0°C)
Hypothermia: axillary temperature <95.9°F (<35.5°C) Hypothermia: axillary temperature ≤95.9°F (≤35.5°C)
Lethargic or less than normal movement Lethargy (movement only with stimulation)
History of feeding problems Feeding difficulty (confirmed by poor suck on examination)
— indicates not included in the algorithm used in this trial.
TABLE 2. Antibiotic Dosage by Weight
Infant Weight  
Range (kg)
Gentamicin
Concentration: 40 mg/mL
Procaine Penicillin
Concentration: 200,000 IU/mL
Amoxicillin
Concentration: 100 mg/mL
Volume (mL) Daily Dose (mg) Volume (mL) Daily Dose (IU) Volume (mL) Daily Dose (mg)
1.500–1.749 0.18 7.20 0.35 70,000 1.6 160
1.750–1.999 0.20 8.00 0.40 80,000 1.9 190
2.000–2.499 0.25 10.00 0.50 100,000 2.3 230
2.500–2.999 0.30 12.00 0.60 120,000 2.8 280
3.000–3.499 0.35 14.00 0.70 140,000 3.3 330
3.500–3.999 0.40 16.00 0.85 170,000 3.8 380
4.000–4.499 0.45 18.00 0.95 190,000 4.3 430
4.500–4.999 0.50 20.00 1.00 200,000 4.8 480
5.000–5.499 0.55 22.00 1.10 220,000 5.3 530
5.500–5.999 0.60 24.00 1.20 240,000 5.8 580
6.000–6.499 0.65 26.00 1.35 270,000 6.3 630
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20 minutes of the second oral dose, the caregiver is instructed to 
seek medical attention. It is not feasible to blind study participants 
or study physicians to treatment group allocation.
Definition of Treatment Failure
the trial’s primary outcome is treatment failure in the 7 days 
after enrolment defined as 1 or more of the following 9 criteria:
1. Any time before the day 8 assessment: Death.
2. On or before the day 8 assessment: Clinical deterioration based 
on the presence of at least 1 of the following 8 danger signs 
documented by the study physician based on physical examina-
tion findings: unconscious, convulsions (may also be diagnosed 
based on convincing history), unable to feed, apnea, cyanosis, 
bulging fontanelle, major bleeding, persistent vomiting (defined 
as vomiting after 3 attempts to feed the baby within half an hour 
as assessed by study physician).
3. On or before the day 8 assessment: Decision by a study physi-
cian to change the antibiotic regimen or add another antibiotic 
for either of the following reasons:
a. new-onset infectious comorbidity (ie, severe omphalitis, bone 
or joint infection, or severe skin or soft tissue infection), or
 b. Serious nonfatal antibiotic-associated adverse event (ie, severe 
diarrhea associated with dehydration, Stevens–Johnson syn-
drome, anaphylaxis or acute renal failure).
4. On or before the day 8 assessment: Hospitalization for any 
reason.
5. On or after day 3: Occurrence of new signs of clinical severe 
infection (any of the 5 signs). A “new” sign is one that was not 
present at the time of enrolment. Signs are defined in the same 
manner as for initial eligibility.
6. On day 4, for infants with multiple signs at enrollment: presence 
of at least 2 of the signs that were present on enrolment;
7. On day 4, for infants with a single sign on enrolment: presence 
of the same sign that was present on enrolment.
8. On or after day 5: Recurrence of at least 1 of the following 
signs: temperature ≥38°C or ≤35.5°C, severe chest indrawing, 
lethargy or poor suck on any follow-up visit. Recurrence implies 
the presence of the sign on enrolment and documented resolu-
tion of the sign on at least 1 follow-up visit with subsequent 
reappearance of the same sign on at least 1 follow-up visit on or 
after day 5.
9. On day 8: persistence of any of the 5 signs of severe infection 
that was present on enrolment.
All surviving infants meeting clinical treatment failure 
criteria by study physicians on routine follow-ups are designated 
as provisional treatment failures and transported to the hospital 
accompanied by study personnel. At the hospital, the infant under-
goes a repeat examination without history-taking by a second study 
physician. to the extent possible, the second physician assessor is 
blinded to the treatment allocation and prior history of the infant. If 
the second assessment supports the ascertainment of treatment fail-
ure, the case is considered a confirmed treatment failure. If the sec-
ond medical assessment disagrees with first assessment, the deci-
sion is referred to a supervising senior physician, whose decision 
is the final determination. Infants designated as treatment failures 
are referred for further hospital care according to standard hospital 
practices. Results of blood cultures may be used to guide specific 
therapy for treatment failures.
A random ~5% subsample of nontreatment failure visits are 
assessed in the home or facility by a second study physician for 
quality control purposes. to the extent that it is feasible, efforts 
are being made to blind the second physician assessor to the first 
physician’s assessment (ie, he/she is not informed as to whether 
an infant has been brought to the hospital because of provisional 
treatment failure or because of random selection). the assessment 
of the second physician does not routinely affect study procedures 
or outcome ascertainment. However, if danger sign(s) are deemed 
to be present by the second physician, the infant is brought to the 
hospital for management and adjudication of treatment failure by 
a third physician.
Data Analysis and Sample Size
We hypothesize that each of the alternative therapies will not 
be inferior to standard therapy and that the treatment failure propor-
tions among infants receiving both the standard therapy (A) and 
alternative therapies (B and C) will be 10%. the alternative thera-
pies will be considered not inferior to the standard therapy if the 
upper bound of the CI for the difference in treatment failure propor-
tions (alternative therapy minus standard therapy) is less than 5%. 
For each comparison (B vs. A; C vs. A), the point estimate of the 
failure rate difference between the 2 treatment arms will be calcu-
lated together with a 2-sided 95% CI. In order to take into account 
any between-group differences in any potentially confounding vari-
ables, the difference will also be expressed as a ratio of the rate in 
alternative therapies to failure rate in standard therapy and model 
using binomial regression models with a log link.
the samples size for this 3-armed study was esti-
mated by the method of Blackwelder30 and the formula 
N
p p p p
p p
=
+( ) −( ) + −( ) 
− −( )
− −
Ζ Ζ
∆
1 2 1 1 1 2 2
1 2
2
1 1α β/
, where p
1
 and p
2
 are
 
the true treatment failure rates in the standard and alterative regi-
mens, respectively, and Δ is the margin used to define similarity. 
table 3 shows the expected power of different effective sample 
sizes to demonstrate the similarity of 2 treatments (with a similar-
ity margin of +5%). It is assumed that the true failure rate in the 
standard treatment arm will be 10% and that the true failure rate 
in the experimental arm will either be identical or only slightly 
worse (11%). enrolment of 750 evaluable children in each of 3 
arms (2250 total) will yield 90% power to demonstrate similarity 
to within +5%, if the true failure rates are identical. If the dif-
ference between the true failure rates between the standard and 
alternative therapy is 1%, the power to demonstrate similarity to 
within +5% will be 71%. Some children may have missed visits, 
incomplete treatment compliance or may be withdrawn from the 
study before the completion of treatment, which will reduce the 
number of children who are eligible for inclusion in the primary 
per-protocol analysis. Infants who receive 100% of the doses of 
scheduled antibiotics on all 7 days or by the time of treatment 
failure if treatment failure occurs, and are not known to have 
received any other antibiotic by study or nonstudy physician, are 
considered “fully adherent” to study treatment. An infant who 
is not fully adherent is considered “partially adherent” if he/she 
received 100% of scheduled antibiotics on days 1–3 or by the 
time of treatment failure; received at least 50% of the scheduled 
doses of each antibiotic during days 4–7, or by the time of treat-
ment failure; is not known to have received any nonstudy inject-
able antibiotic before day 8 assessment; and is not known to have 
received any nonstudy oral antibiotic on days 1–3. Infants who 
do not fulfill the criteria of either fully or partially adherent are 
considered nonadherent. Infants who receive scheduled follow-up 
on all 7 days or up-to the time of treatment failure if treatment 
failure occur are considered to have complete clinical follow-up. 
An infant is considered to have partial clinical follow-up if he/
she has 1 or more days of follow-up missing, but follow-up was 
completed on assessment days 2–4 and on at least 1 of days 5–8, 
and vital status on day 8 was known. Infants who do not fulfill 
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the criteria of complete or partial clinical follow-up are consid-
ered to have incomplete clinical follow-up. the primary analysis 
will be a modified per-protocol analysis that includes infants with 
either complete or partial follow-up and who are either fully or 
partially adherent. Infants with either incomplete clinical follow-
up or who are nonadherent are considered lost to follow-up and 
will be excluded from the primary analysis. Based on previous 
experience in similar settings, we have allowed for up to 15% loss 
to follow-up, and therefore will aim to enroll 866 children to each 
arm or 2598 total.
Approvals
this study was reviewed and approved by the Johns Hopkins 
Bloomberg School of public Health’s Institutional Review Board, 
the Bangladesh Institute of Child Health’s ethical Review Commit-
tee and the WHO’s Research ethics Review Committee.
DISCUSSION
Results from the Bangladesh simplified antibiotic regimens 
trial are expected to be made available in late 2013. the trial will 
determine whether the 2 antibiotic treatment regimens that include 
fewer doses of parenteral antibiotics are as efficacious as standard 
parenteral antibiotic treatment in young infants with signs of severe 
infection. Clinical equipoise exists because the relative efficacies of 
various antibiotic regimens for clinical severe infection in infants 
less than 2 months old are unknown in the outpatient setting. the 
findings are expected to inform decisions related to the scale-up of 
community-based care of young infant infections.
In this home-based trial in a highly vulnerable population, 
an obligation to protect the safety of participants exists alongside 
the duty to generate evidence that can guide practical policy deci-
sions in the resource-poor context. A central ethical issue is that all 
arms of the trial involve the implementation of antibiotic therapy 
in the outpatient setting, a method of treatment delivery that is not 
standard of care for clinical severe infection in young infants but 
has been successfully implemented in resource-poor settings. this 
trial is designed not to challenge the appropriateness of hospitali-
zation as a universal standard of care, but to develop an evidence 
base relevant to infants for whom hospitalization is not feasible or 
refused by parents/caregivers.
Hospitalization refusal is common in Bangladesh and many 
other similar settings. A pilot study for this trial found that caregiv-
ers refuse hospitalization because of perceived financial burdens 
and concern about potential disruptions to family life, such as pro-
vision of care for older children at home while a mother remains in 
hospital with her young infant. Bed shortages are also common at 
the participating hospitals. When no bed is available, the standard 
procedure is to recommend that the family take the baby to another 
hospital, but families rarely pursue this alternative because pediat-
ric bed availability at other public hospitals is limited, travel costs 
may be prohibitive or other factors.
therefore, in designing this trial, the study investigators, the 
trial steering committee and protocol reviewers were faced with a 
situation in which sick infants may go without care when hospitaliza-
tion would be ideal, and thus conducting the trial would represent an 
expansion of clinical services for the community. However, we did 
not want the implementation of the trial to further discourage fami-
lies from accepting hospitalization when that would be the preferred 
treatment option from a medical perspective. For this reason, families 
are not offered study participation unless: (1) caregivers refuse to 
accept hospitalization, or (2) no bed is available at the study hospital 
and referral to another hospital is refused or deemed impracticable. 
We have instituted procedures designed to diminish the potential for 
unduly influencing caregivers to accept home-based treatment when 
a hospital bed is available. Hospital staff have been instructed to avoid 
any discussion of the study with parents of prospective participants 
until after a spontaneous refusal of admission after diagnosis and 
suggested treatment plan occurs, or it is determined that no beds are 
available. the study physician is required to document that attempts 
were made to convince the caregivers to consent to hospital admis-
sion. Referring or treating physicians are not rewarded, financially 
or otherwise, on the basis of the number of prospective participants 
referred, nor are study physicians coinvestigators, in which case they 
could have academic interests at stake. Before families enroll in the 
study, they meet separately with trained study personnel called coun-
selors whose role is to discuss their decision to refuse hospitalization 
at the study hospital. the counselor’s primary role is to ensure that 
the caregivers understand that the study physician has recommended 
that the infant be admitted to hospital based on current standard care 
of clinical severe infection and to confirm that the family has refused 
hospital admission despite counseling.
TABLE 3. Power of Different Effective Sample Sizes to Demonstrate the Similarity of 2 Treatments (With a 
Similarity Margin of +5%) Under Different Assumptions About True Similarity of the 2 Treatments (Identical or 
Difference of 1% in True Failure Rates)
True Failure Rate in 
Group A (%)
True Failure Rate in 
Groups B or C (%)
Number of Per-protocol 
Children per Arm
Allowed Similarity 
Margin (%)
Probability That Study Will Demon-
strate Similarity of the 2 Treatments 
Within the Allowable Margin (%)
10 10 550 +5 79
10 10 600 +5 82
10 10 650 +5 85
10 10 700 +5 88
10 10 750 +5 90
10 10 800 +5 92
10 10 850 +5 93
10 10 1500 +5 99
10 11 550 +5 58
10 11 600 +5 62
10 11 650 +5 65
10 11 700 +5 68
10 11 750 +5 71
10 11 800 +5 74
10 11 850 +5 77
10 11 1500 +5 95
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